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STATE-OF-THE-ART PAPER STATE-OF-THE-ART PAPER995Complications Rates With ICDs and CRTJohannes B. van Rees, Miha´ly K. de Bie, Joep Thijssen, C. Jan Willem Borleffs, Martin J. Schalij,
Lieselot van Erven
Despite abundant data on the beneficial effects of implantable cardioverter-defibrillators
(ICDs) and cardiac resynchronization therapy (CRT), less is known regarding the safety and
complication rates of implantations. van Rees and colleagues systematically reviewed 11 ICD
and 7 CRT trials to provide data on the frequency of in-hospital mortality and complications
related to the implantation. Average in-hospital mortality was 2.7%, driven primarily by high
mortality rates in early post-myocardial infarction trials. The mortality rate was 0.2% in trials
utilizing nonthoracotomy ICDs and 0.3% in CRT trials. The pneumothorax rate was similar
between the nonthoracotomy ICD and CRT trials (0.9%). Coronary sinus dissection or
perforation occurred in 2.0% of CRT patients. Lead dislodgement rates were higher in CRT
trials (5.7%) than in nonthoracotomy ICD trials (1.8%).CLINICAL RESEARCH HEART RHYTHM DISORDERS1001Recent Increase in Rate of Infection for ICD DevicesArnold J. Greenspon, Jasmine D. Patel, Edmund Lau, Jorge A. Ochoa, Daniel R. Frisch, Reginald T. Ho,
Behzad B. Pavri, Steven M. Kurtz
Greenspon and colleagues analyzed the rate of infection of cardiac implantable electrophysiologic
devices (CIEDs) (i.e., pacemakers and implantable cardioverter-defibrillators) in the United
States. The Nationwide Inpatient Sample (NIS) discharge records were queried to determine
this rate over time. During the entire study period (1993 to 2008), the incidence of CIED
infection was 1.6%. The annual rate of infections remained constant until 2004, when a
marked increase was observed, which coincided with an increase in the incidence of major
comorbidities and mortality. These results suggest that the increasing use of CIEDs in
patients with multiple comorbidities has led to an increase in device-related infections.(continued on page A-18)
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aHEART RHYTHM DISORDERS1007Higher Rates of Complications and Mortality With Dual-Chamber ICDsThomas A. Dewland, Cara N. Pellegrini, Yongfei Wang, Gregory M. Marcus, Edmund Keung,
Paul D. Varosy
While dual-chamber implantable cardioverter-defibrillators (ICDs) offer theoretical advantages
over single-chamber devices, the clinical superiority of dual-chamber models has not been
proven, and they may increase the risk of complications. Dewland and colleagues reviewed
data from the National Cardiovascular Data Registry ICD Registry on 100,000 patients who
received an ICD. Dual-chamber devices were used in 62%, yet only 40% of these patients
had an indication for pacemaker therapy. After adjusting for demographics, medical
comorbidities, diagnostic test data, and ICD indication, the odds of any complication
(odds ratio [OR]: 1.40) and in-hospital mortality (OR: 1.45) were increased with dual-
versus single-chamber ICD devices. Patients who received dual-chamber devices had higher
procedure-related complications and in-hospital mortality when compared with single-
chamber recipients.Editorial Comment: Amin Al-Ahmad, James V. Freeman, p. 1014INTERVENTIONAL CARDIOLOGY1016TAVI Safe and Effective With Small Aortic AnnulusDimitri Kalavrouziotis, Josep Rodés-Cabau, Rodrigo Bagur, Daniel Doyle, Robert De Larochellière,
Philippe Pibarot, Eric Dumont
A small aortic annulus increases the risks of surgical repair of severe aortic stenosis (AS),
either through patient–prosthesis mismatch or aortic annuloplasty. Kalavrouziotis and
colleagues reviewed the valve hemodynamics and clinical outcomes among patients with a
small aortic annulus who underwent transcatheter aortic valve implantation (TAVI). A total
of 35 patients with severe AS and an aortic annulus diameter 20 mm underwent TAVI.
rocedural success was achieved in 97% of patients, with 1 in-hospital death and marked
mprovements in valve hemodynamics. At a mean follow-up of 14 months, transvalvular
radients remained low, and 30 of the 31 remaining survivors were in New York Heart
ssociation functional class I or II. In high-risk patients with severe AS and a small aortic
nnulus, TAVI appears to be a reasonable alternative to conventional aortic valve replacement.(continued on page A-21)
AUGUST 30, 2011 (continued) A-21CARDIOVASCULAR RISK1025Homocysteine Levels Improve Cardiac Risk PredictionVikas Veeranna, Sandip K. Zalawadiya, Ashutosh Niraj, Jyotiranjan Pradhan, Brian Ference,
Robert C. Burack, Sony Jacob, Luis Afonso
Veeranna and colleagues used data from the MESA (Multi-Ethnic Study of Atherosclerosis)
dataset and NHANES III (National Health and Nutrition Examination Survey III) to
determine if adding homocysteine (Hcy) to a model with traditional cardiovascular disease
(CVD) risk factors improves cardiac risk prediction. Hcy (15 mol/l) significantly predicted
CVD (adjusted hazard ratio [aHR]: 1.79) and coronary heart disease (CHD) events (aHR:
2.22) in MESA, and CVD (aHR: 2.72) and CHD mortality (aHR: 2.61) in NHANES III
after adjustments for traditional risk factors and C-reactive protein. Hcy levels led to
significant reclassifications in the intermediate-risk population. These results show that Hcy
significantly improves risk prediction beyond the Framingham risk score in an ethnically
diverse population at intermediate risk for CHD events.Editorial Comment: Arduino A. Mangoni, Richard J. Woodman, p. 1034HEART FAILURE1036Risks of Cardiac Transplantation After a Cerebrovascular EventVishnu Patlolla, Vanajakshi Mogulla, David DeNofrio, Marvin A. Konstam, Rajan Krishnamani
Symptomatic cerebrovascular disease (sCVD) is considered a relative contraindication to heart
transplantation, but has not been well studied. Patlolla and colleagues reviewed data from the
United Network for Organ Sharing Registry. There were 1,078 patients with sCVD and
16,765 patients without sCVD who underwent a cardiac transplant. There were higher rates
of stroke, death, and functional decline in patients with sCVD than in patients without
sCVD, but the risk of death was no longer significant after multivariable adjustment. These
results should help programs make informed decisions about patients with sCVD who are
being evaluated for heart transplantation.
Editorial Comment: Wayne C. Levy, Todd Dardas, p. 1042(continued on page A-22)
AUGUST 30, 2011 (continued) A-22CARDIAC IMAGING1044CMR for Evaluation of Pediatric Cardiac MassesRebecca S. Beroukhim, Ashwin Prakash, Emanuela R. Valsangiacomo Buechel, Joseph R. Cava,
Adam L. Dorfman, Pierluigi Festa, Anthony M. Hlavacek, Tiffanie R. Johnson, Marc S. Keller,
Rajesh Krishnamurthy, Nilanjana Misra, Stephane Moniotte, W. James Parks, Andrew J. Powell,
Brian D. Soriano, Monvadi B. Srichai, Shi-Joon Yoo, Jing Zhou, Tal Geva
Beroukhim and colleagues developed a set of criteria for the evaluation and diagnosis of
cardiac tumors in children and then solicited cases from an international cohort to test the
utility of the criteria in patients with a confirmed histologic diagnosis. A total of 78 cases
were submitted from 15 centers. Reviewers who were blinded to the histologic diagnoses
correctly diagnosed 97% of the cases, but included a differential diagnosis in 42%. Better
image quality and a more complete examination were associated with higher diagnostic
accuracy. Cardiac magnetic resonance (CMR) can predict the likely tumor type in the
majority of children with a cardiac mass, and the imaging characteristics of various tumor
types are revealed.Editorial Comment: Dianna M. E. Bardo, p. 1055BIOMARKERS1057MR-proADM Levels Predict Mortality in Patients Presenting With Acute DyspneaAHF, MR-proADM<1.985 nmol/l, n=411, deaths=30
AHF, MR-proADM>1.985 nmol/l, n=153, deaths=34
Non-AHF, MR-proADM<1.985 nmol/l, n=1004, deaths=44
Non-AHF, MR-proADM>1.985 nmol/l, n=67, deaths=21
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Christopher Hogan, Alan H. B. Wu, Mark Richards, Paul Clopton, Gerasimos S. Filippatos,
Salvatore Di Somma, Inder Anand, Leong L. Ng, Lori B. Daniels, Sean-Xavier Neath, Robert Christenson,
Mihael Potocki, James McCord, Oliver Hartmann, Nils G. Morgenthaler, Stefan D. Anker
The recently published BACH (Biomarkers in Acute Heart Failure) study demonstrated that
midregion proadrenomedullin (MR-proADM) had superior accuracy for predicting 90-day
mortality compared with B-type natriuretic peptide (BNP) in patients with acute heart failure
(AHF). This study reports on the prognostic utility of MR-proADM in patients presenting
with acute shortness of breath. Compared with BNP or troponin, MR-proADM was
superior for predicting 90-day all-cause mortality. Serial evaluation of MR-proADM
performed in admitted patients provided a significant added value compared with a model
with the admission values only. MR-proADM identifies patients with high 90-day mortality
and adds prognostic value to natriuretic peptides in patients presenting with acute shortness of
breath, irrespective of their final diagnosis.(continued on page A-24)
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1068LDL Lowering Does Not Improve Tissue Perfusion or
Metabolism in Patients With PADAmy M. West, Justin D. Anderson, Frederick H. Epstein, Craig H. Meyer, Hongkun Wang,
Klaus D. Hagspiel, Stuart S. Berr, Nancy L. Harthun, Arthur L. Weltman, Joseph M. DiMaria,
Jennifer R. Hunter, John M. Christopher, Christopher M. Kramer
West and colleagues hypothesized that low-density lipoprotein (LDL) reduction would
improve calf muscle perfusion, energetics, or walking performance in patients with peripheral
arterial disease (PAD) as measured by magnetic resonance imaging (MRI) and magnetic
resonance spectroscopy (MRS). A total of 68 patients with mild-to-moderate symptomatic
PAD were studied at baseline and annually for 2 years after beginning simvastatin 40 mg,
simvastatin 40 mg/ezetimibe 10 mg if statin-naïve, or ezetimibe 10 mg if already on a statin.
Phosphocreatine recovery time was measured with MRS, calf perfusion was measured using
first-pass contrast-enhanced MRI, and 6-min walk distance was recorded. Despite effective
LDL reduction, tissue perfusion, metabolism, and exercise parameters did not improve,
although rest ankle-brachial index improved. This small, nonplacebo-controlled trial shows
that LDL lowering does not improve calf muscle physiology or functional capacity in PAD.Editorial Comment: Mitchell W. Krucoff, W. Schuyler Jones, Manesh R. Patel, p. 1077
